Team
Our team has extensive experience in the development, authorisation and marketing of therapeutic adsorbers.
Dr. Ahmed Sheriff – CEO
During his time at university, he specialised in the immunology of inflammatory diseases. He was Managing Director of the European Federation of Immunological Societies and the German Society for Immunology. He has many years of experience as an entrepreneur, which he gained at Genethor GmbH and Pentracor GmbH. He is involved as inventor or co-inventor in more than 20 patents/applications.
Birgit Vogt – Scientific Director
Through her work at the Fraunhofer Institute for Toxicology and Aerosol Research, the Heinrich Pette Institute and Charité - University Medicine, the graduate engineer (FH) in biotechnology has many years of experience in applied medical research. She has already been responsible for the organisation of research and development at Genethor GmbH and Pentracor GmbH. She is also a lecturer at the Berlin University of Applied Sciences. She is involved as (co-)inventor in more than 10 patents / patent applications.
Christopher Bock – Head of Market Development and Clinical Research
The veterinarian began working on CRP apheresis in 2008. Initially, he was responsible for planning, conducting and evaluating the necessary animal experiments in Dr. Sheriff's research group at the Charité. At Pentracor GmbH he designed and supervised the clinical studies on CRP apheresis together with his colleagues as Deputy Head of Clinical Research. He then managed market development and introduced CRP apheresis to the hospitals using it as a senior medical device consultant.
Daniel Kaiser - Head of Finance department
After more than 25 years working for a pan-European retailer, the business administration graduate (FH) took over as head of finance at a medical device manufacturer and is now also responsible for this area at Capture Biotech. He also has many years of experience in training managers.
Gülcan Yapici – QMR and Head of the Regulatory Affairs department
The graduate engineer (FH) in biotechnology has many years of experience as QMR (Quality Management Representative) and Head of Regulatory Affairs at a medical device manufacturer certified according to EN ISO 13485:2016. She has accompanied the entire process from development to market launch and was also PRRC (Person Responsible for Regulatory Compliance according to Art. 15 MDR).
Dr.-Ing. Gunnar Janelt – Head of Production
From 1999 to 2005, the biotechnologist was head of production at Affina Immuntechnik GmbH (later taken over by Fresenius Medical Care Affina GmbH), where he set up the production of immunoadsorption columns. He developed the production processes and was involved in the design and establishment of the quality management system. He then worked at the Charité - University Medicine. There he worked on the development of a liver support system in the ‘Liver Dialysis’ research project. From 2011 - 2024 he was head of production at a manufacturer of therapeutic adsorbers. He is co-inventor on 3 patent applications.
Stephan Mattecka – Head of IT and Deputy Head of R&D
The biochemist has 13 years of experience in the development of therapeutic adsorbers. He has also been in charge of the IT infrastructure for the same length of time, including 10 years in an EN ISO 13485:2016 regulated environment. He was also responsible for the statistical planning and analysis of clinical trials. He is co-inventor on several patents / patent applications.
Wolfgang Richter – Head of Quality Control
The graduate engineer (FH) in biotechnology has many years of experience as Head of Quality Control in an EN ISO 13485:2016 certified company. There he developed, established and improved numerous control processes.
Collaborators
Prof. Gregg W. Stone
Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine and Population Health Sciences and Policy in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 140 national and international multicenter randomized trials, many of which have led to new device approval or indications in the US; has authored more than 3000 manuscripts and abstracts published in the peer-reviewed literature; and has delivered thousands of invited lectures around the world. With a 2022 H-index factor of 185, Dr. Stone has been listed in Nature Medicine as one of the most highly cited authors (top 0.1%) in science.
